Medical/Safety Monitoring 

The Therapeutics Development Network (TDN) Coordinating Center can provide coverage and coordination for the review and reporting of serious adverse events (SAEs) that may occur during the course of CF clinical studies.

Our Chief Medical Officer, who oversees the medical monitoring program and serves as the primary medical monitor on studies, is a pulmonologist with experience in CF clinical care, clinical trial conduct and safety monitoring.

In addition to SAE monitoring, the medical monitor is available to review all adverse events listings on a regular basis in order to identify any unexpected events or trends.

Related Information 

For more about other services offered through the TDN Coordinating Center, see the following:

Contact Us 

back to top

Updated 2/12/13